ArticleThe Journal of infectious diseases2022
Understanding the Potential Drivers for Respiratory Syncytial Virus Rebound During the Coronavirus Disease 2019 Pandemic.
Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Characterising the asynchronous resurgence of common respiratory viruses following the COVID-19 pandemic.Nature communications · 2025Pooled it
- Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.The Lancet. Infectious diseases · 2024Pooled it
- Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.The Lancet. Infectious diseases · 2024Pooled it
- The role of respiratory co-infection with influenza or respiratory syncytial virus in the clinical severity of COVID-19 patients: A systematic review and meta-analysis.Journal of global health · 2022Pooled it
- Epidemiological Characteristics of Respiratory Syncytial Virus in Pediatric Acute Lower Respiratory Tract Infections in Baoding, Hebei Province of China, from 2017 to 2024.Children (Basel, Switzerland) · 2026Article
- Epidemic dynamics and age-specific distribution of respiratory pathogens: a direct-to-consumer surveillance study in four regions of China, October 2023-February 2025.BMC infectious diseases · 2026Article
- Estimating the burden of RSV- and influenza-associated ED visits, hospitalizations, ICU admissions, and deaths across age and socioeconomic groups in New York State, 2005-2019.BMC infectious diseases · 2026Article
- Respiratory viral coinfections: interactions, mechanisms and clinical implications.Nature reviews. Microbiology · 2025Review
- The seasonality of respiratory syncytial virus and its associations with meteorological factors in Hong Kong, 2014-2023.One health (Amsterdam, Netherlands) · 2025Article
- Post-COVID-19 resurgence of respiratory viruses in Taiwan: an interrupted time series analysis from three regional medical centers (2015-2023).BMC infectious diseases · 2025Article
- Article
- Experimental Models to Investigate Viral and Cellular Dynamics in Respiratory Viral Co-Infections.Microorganisms · 2025Review
- Resurgence of Mycoplasma pneumoniae infections in children: emerging challenges and opportunities.Current opinion in infectious diseases · 2025Review
- Impact of COVID-19 pandemic on childhood asthma and wheezing disorders.World journal of pediatrics : WJP · 2025Article
- Respiratory Virus Prevalence Across Pre-, During-, and Post-SARS-CoV-2 Pandemic Periods.Viruses · 2025Article
- An outbreak of human respiratory syncytial virus infection in the rural community of Zhejiang Province in 2023.Annals of medicine and surgery (2012) · 2025Article
- Seasonal epidemiological and clinical characteristics of pediatric patients with respiratory syncytial virus infection by age during COVID-19: a cross-sectional study.Translational pediatrics · 2025Article
- Hospitalizations for all-cause pediatric acute respiratory diseases in Alberta, Canada, before, during, and after the COVID-19 pandemic: a population-level retrospective cohort study from 2010 to 2024.Lancet regional health. Americas · 2025Article
- Incidence and severity of community acquired pneumonias in children before and after the COVID-19 pandemic.Journal of public health (Oxford, England) · 2025Article
- Multiple Respiratory Virus Detection in Acute Respiratory Infection Patients in Mie Prefecture, Japan, 2021-2023.Viruses · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
Nonpharmaceutical interventions (NPIs) were widely introduced to combat the coronavirus disease 2019 (COVID-19) pandemic. These interventions also likely led to substantially reduced activity of respiratory syncytial virus (RSV). From late 2020, some countries observed out-of-season RSV epidemics. Here, we analyzed the role of NPIs, population mobility, climate, and severe acute respiratory syndrome coronavirus 2 circulation in RSV rebound through a time-to-event analysis across 18 countries. Full (re)opening of schools was associated with an increased risk for RSV rebound (hazard ratio [HR], 23.29 [95% confidence interval {CI}, 1.09-495.84]); every 5°C increase in temperature was associated with a decreased risk (HR, 0.63 [95% CI, .40-.99]). There was an increasing trend in the risk for RSV rebound over time, highlighting the role of increased population susceptibility. No other factors were found to be statistically significant. Further analysis suggests that increasing population susceptibility and full (re)opening of schools could both override the countereffect of high temperatures, which explains the out-of-season RSV epidemics during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.